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RECK is downregulated in many types of tumors. Forced 
expression of RECK inhibits tumor angiogenesis, invasion, 
metastasis, and/or proliferation, depending on the cell sys-
tem.1–5 However, the molecular mechanisms of RECK down-
regulation in tumor cells remain largely unknown.
The epithelial–mesenchymal transition (EMT) is a pro-
cess by which epithelial cells lose their apicobasal polarity and 
cell–cell adhesion and gain migratory and invasive properties, 
resembling those of mesenchymal cells. EMT is essential for 
numerous developmental processes, including mesoderm for-
mation and neural tube formation. EMT has also been shown 
to occur during wound healing, organ fibrosis, cancer inva-
sion, and metastasis.6,7
Accumulating evidence indicates the involvement of 
a number of microRNAs (miRs) in the process of carcino-
genesis, as well as cancer progression.8 Based on their activi-
ties, cancer-associated miRs can be divided into two groups: 
oncomiRs and tumor suppressor miRs. A single miR may 
target multiple mRNAs, while one mRNA may be tar-
geted by multiple miRs, providing a basis for an intricate 
network of gene regulation. Hence, bioinformatic analyses 
and evaluation of large sets of data and publications already 
accumulated in this field of studies should be a reasonable 
approach for deducing the cellular functions of miRs. For 
example, numerous papers on miRs relevant to EMT as well 
as miRs induced by various stimuli (such as hypoxia and 
growth factors) and targeting RECK mRNA have already 
been published (see below).
We previously found that TGFβ-induced EMT was 
accompanied by RECK upregulation in nontumorigenic 
epithelial cell lines (MCF10A and HMLE), but not in 
carcinoma- derived cell lines (MCF7 and A549).9 RECK over-
expression did not affect the process of EMT but negatively 
regulated cell proliferation and migration. Although the exact 
mechanisms by which RECK expression is uncoupled from 
EMT in cancer cells remain to be elucidated, one obvious pos-
sibility is transcriptional repression of RECK gene in cancer 
cells. However, we found some discrepancy between the lev-
els of RECK mRNA and RECK protein in cancer cells and, 
therefore, speculated whether some cancer-associated miRs 
might also play roles in this uncoupling. To address this ques-
tion in this study, we first attempted to find candidate miRs 
using three approaches in silico: (1) text mining to extract 
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miRs enriched in studies of cancer EMT, (2) prediction of 
miRs targeting RECK mRNA, and (3) analysis of TCGA 
breast cancer miR-seq and RECK mRNA data using a newly 
developed nonparametric correlation test. These approaches 
point to the involvement of the miR-183-96-182 cluster in the 
uncoupling of RECK expression from EMT in cancer cells. 
We also searched for candidate transcription factors involved 
in this event using ENCODE, transcription factor ChIP-seq 
data, ONCOMINE gene expression database, and expres-
sion datasets deposited in NCBI GEO. We propose a testable 
hypothesis based on these findings.
Methods
collecting relevant abstracts from PubMed. The 
following sets of key words were used to collect relevant 
abstracts of original papers from PubMed: for EMT-
associated miRs in noncancerous cells, (microRNA[Title/
Abstract] OR miRNA[Title/Abstract] OR miR[Title/
Abstract]) AND (EMT[Title/Abstract] OR “epithelial-
mesenchymal transition”[Title/Abstract] OR “epithelial-to-
mesenchymal”[Title/Abstract]) NOT (cancer[Title/Abstract] 
OR metastasis[Title/Abstract] OR carcinoma[Title/Abstract] 
OR sarcoma[Title/Abstract] OR tumor[Title/Abstract] OR 
“review”[Publication Type]) and for EMT-associated miRs 
in cancer, (microRNA[Title/Abstract] OR miRNA[Title/
Abstract] OR miR[Title/Abstract]) AND (EMT[Title/
Abstract] OR “epithelial-mesenchymal transition”[Title/
Abstract] OR “epithelial-to-mesenchymal”[Title/Abstract]) 
AND (cancer[Title/Abstract] OR metastasis[Title/Abstract] 
OR carcinoma[Title/Abstract] OR sarcoma[Title/Abstract] 
OR tumor[Title/Abstract]) NOT “review”[Publication Type]. 
The search was performed on November 2, 2015. The abstracts 
were downloaded as .txt files.
text mining for mirs with differences between non-
cancerous and cancer cells. We used R package “pubmed.
mineR”10 to process the abstracts from PubMed. This pro-
vided a correspondence table “HGNCdata” that includes 
approved symbol, approved name, gene synonyms, and so 
on for genes, but not for miRs. Therefore, we acquired miR-
related information from the HUGO Gene Nomenclature 
Committee (HGNC) website.11 In the abstracts, several alias/
synonyms are used to describe the same miR. Thus, we first 
mapped the prefix “miR-”, “microRNA-”, “MicroRNA-”, 
“hsa-miR-”, and “mmu-miR-” to the same character “MIR”, 
converting the alias in the abstract to the approved symbol, 
according to HGNC. The converted abstracts were analyzed 
using pubmed.mineR; we first used the gene_atomization 
function to extract the miRs mentioned in the abstracts and 
then used the searchabsT function to count the abstracts that 
referred to each miR. For each miR referred, we calculated its 
proportion to all papers describing cancer EMT or noncan-
cer EMT and tested the null hypothesis that the proportion 
in cancer EMT = proportion in noncancer EMT using two-
tailed prop.test.
Prediction of mir targets. We used four commonly used 
tools for predicting miRs: miRanda (August 2010 release),12,13 
PicTar,14 TargetScan,15–17 and MicroT-CDS (microT v4).18 
For miRanda, we used human target site predictions with 
good mirSVR score and conserved miR. PicTar predictions 
in vertebrates were used with the default setting to search for 
all miRs potentially targeting RECK, and to evaluate them 
based on the PicTar score. TargetScan was used with the 
default setting, and the Context score and PCT (probability of 
conserved targeting) were used to evaluate the probability of 
a miR to bind RECK 3’-UTR. For microT-CDS, we used the 
gene symbol “RECK”, gene ID “ENSG00000122707”, spe-
cies “Homo sapiens”, and Ensembl version 69 from homolo-
gous genes. The results were evaluated using the miTG score.
data collection from tcGA. We acquired the breast 
invasive carcinoma dataset from the TCGA website19 on May 3, 
2013. From the total 905 breast cancer cases, we extracted 
53 cases for which mRNA and miR data on both cancer tis-
sues and matched normal breast tissues were available. In the 
TCGA project, mRNA expression data had been acquired 
using Agilent 244K Custom Gene Expression G4502A-07 
platform (alias: AgilentG4502A_07). miR-seq data had been 
obtained using Illumina Genome Analyzer (alias: illuminaga) 
system or Illumina Hiseq (alias: illuminahiseq) system. For 
miR-seq analysis, we used the level 3 data (ie, expression calls 
for miRs per sample). In the case of mRNA, we used level 
2 data (ie, normalized signals per probe) and averaged the 
expression calls of the probes that correspond to the same gene 
to obtain a single value for each gene. Agilent G4502A_07 
contains five probes for RECK. From them, we chose to use 
two (A_23_P83028 and A_23_P83030) that were corre-
sponding to the 3’-UTR of the full-length RECK transcript; 
the other three probes were ignored in this study, since they 
may also pick up smaller transcripts whose functions are pres-
ently unclear (Supplementary Fig. 1). To avoid division by zero 
in calculation, we assigned the uniform value of 0.1 to all cases 
in which the miR expression was undetectable.
The paired data correlation test. To facilitate evaluation of 
the trends in expression changes, we developed a nonparamet-
ric method as follows: by setting appropriate cutoff values, the 
expression change between a pair of measurements was catego-
rized into three groups (up, down, and no change) and labeled 
accordingly (1, −1, and 0, respectively). We call this label “Value 
of Change”. To compare the changes in two factors (eg, a miR 
vs. RECK mRNA), the absolute value of the difference between 
two Values of Changes was used for evaluation; we call this 
parameter “diff”. Thus, diff = 0 indicates two factors chang-
ing toward the same direction, diff = 1 indicates no change in 
one factor and up or down in the other, and diff = 2 indicates 
two factors changing toward the opposite directions. To evalu-
ate the trends of changes in multiple pairs of data (eg, multiple 
patients), the sum of diff (termed “diff.sum” score) was used. In 
this case, a smaller diff.sum score indicates a trend of two factors 
changing toward the same direction, whereas a larger diff.sum 
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score indicates a trend of two factors changing toward opposite 
directions. The P-value for each diff.sum score was calculated 
by simulation to evaluate how likely the diff.sum score can be 
obtained by chance. Specifically, we first got a vector containing 
53 diff values for RECK mRNA and a 1046 × 53 matrix con-
taining diff values for 1046 miRs in 53 patients. We then simu-
lated a 1000 times larger matrix, 1,046,000 × 53, by randomly 
shuffling the position of patients in the original diff matrix for 
miRs, while keeping the RECK diff vector unchanged. Using 
the RECK diff vector and the simulated diff matrix for miRs, 
we obtained 1,046,000 diff.sum scores. Probabilities for each 
specific diff.sum were then calculated based on the distribu-
tion of the 1,046,000 diff.sum scores. The concept of this non-
parametric correlation test for paired data, which we termed the 
paired data correlation (PDC) test, is illustrated in Figure 1. 
Based on the distribution of RECK mRNA and miRs in can-
cer and normal breast tissues, we chose cutoff values of 0.8 and 
1.25 (±0.3219 in log2), respectively, for the downregulation and 
upregulation of RECK mRNA, respectively, and 0.5 and 2.0 
(±1 in log2) for those of miRs.
Analysis of the mir-183-96-182 promoter. UCSC 
Genome Browser on Human Feb. 2009 (GRCh37/hg19) 
Assembly20 was used to search for possible transcription fac-
tors of the miR-183-96-182 cluster. Based on the tracks related 
to regulation (eg, Integrated Regulation from ENCODE 
Tracks)21 and the position of transcription start site (TSS) of 
the miR-183-96-183 cluster, we decided to focus on the region 
up to 16 kb upstream of the miR-183 precursor. Transcription 
factors suggested to bind this region by the Transcription Fac-
tor ChIP-seq (161 factors) from ENCODE with Factorbook 
Motifs were extracted manually.
survey of gene expression profile data. We screened 
gene expression profile data from knockdown, knockout, 
overexpression, or inhibitor treatment experiments relevant to 
candidate transcription factors. The NCBI GEO datasets that 
include information on miR-183-96-182 cluster were based 
mainly on three platforms, namely, Illumina HumanHT-12 
V4.0 expression beadchip (GPL10558), Affymetrix Mouse 
Gene 1.0 ST Array (GPL6246), and Affymetrix Human 
Gene 1.0 ST Array (GPL6244). These data were acquired 
Phase 1: Consider one factor (gene or miR) in one pair of samples
Phase 2: Consider relation of two factors in one pair of samples
Phase 3: Consider relation of two factors in multiple (m) pairs of samples
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figure 1. algorithm of paired data correlation (PDC) test.
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using R package “GEOquery”,22 and the values for multiple 
probes corresponding to the same gene ID were averaged 
to obtain a representative value for each gene. For impor-
tant candidates, we extended our search to other array-based 
platforms as well as RNA-seq data. We also used ONCOM-
INE 4.523 to find the trends in expression of candidate tran-
scription factors for miR-183-96-182 in various cancers. 
The thresholds used were P-value = 0.001, fold change = 2, 
and gene rank = top 10%.
results
text mining for papers describing mirs involved in 
cancer eMt and noncancer eMt. To examine our hypoth-
esis that miRs may play roles in uncoupling RECK expres-
sion from EMT in cancer, we first surveyed original papers 
in PubMed describing miRs involved in cancer EMT and 
noncancer EMT using the key word sets described in the 
“Methods” section. This literature search yielded 887 papers 
on cancer EMT and 145 papers on noncancer EMT. The most 
reported miRs in cancer EMT were members of the miR-200 
family: miR-200c (121 papers), miR-200b (75 papers), and 
miR-200a (59 papers). The most reported miR in noncancer 
EMT was miR-21 (20 papers), which has also been associ-
ated with cancer EMT (53 papers). Some miRs have only 
been associated with cancer EMT. For example, miR-22 has 
been associated with cancer EMT in 25 papers, but never 
with noncancer EMT. In total, 40 miRs have been associ-
ated with cancer EMT in more than three papers but never 
with noncancer EMT (Supplementary Table 1), although the 
specificity of association was statistically significant only in a 
few cases (probably because of the paucity of noncancer stud-
ies). Representative miRs are shown in Table 1.
target prediction implicates mir-182 in uncou-
pling of recK expression from eMt in cancer. Second, 
we screened for miRs potentially targeting RECK mRNA 
using four algorithms as follows: miRanda, TargetScan, 
PicTar, and DIANA-microT. These algorithms evaluate the 
following features in different combinations and emphases: 
(1) base pairing pattern between a miR and a possible target, 
(2) thermodynamic stability of miR-mRNA hybrid, and 
(3) conservation of target sequences across related species. 
Despite the differences in their theoretical bases and compu-
tational procedures,24 the results from these four algorithms 
showed considerable overlap. Among the 16 miRs with an 
mirSVR score (miRanda) less than −1.2, 6 miRs were also 
detected with the other algorithms (Table 2). Of note, miR-
182 gave the top score with miRanda (mirSVR) and high 
scores with Pictar (PicTar score), TargetScan (Context score 
and PCT), and MicroT-CDS (miTG score; Table 2 and Sup-
plementary Tables 2–5).
Table 1. number of original research papers describing mirs in the context of cancer and/or noncancer emt.
miR CANCER EMT NoNCANCER EMT RATio (CANCER/NoNCANCER) P-vAlUE
(1) mir-22 25 (0.028) 0 (0.000) 0.041
mir-10b 11 (0.012) 0 (0.000) 0.178
mir-222 11 (0.012) 0 (0.000) 0.178
mir-143 9 (0.010) 0 (0.000) 0.223
(2) mir-200c 121 (0.136) 10 (0.069) 1.978 0.024
mir-200b 75 (0.085) 11 (0.076) 1.115 0.726
mir-200a 59 (0.067) 9 (0.062) 1.072 0.841
mir-21 53 (0.060) 20 (0.138) 0.433 0.001
mir-141 34 (0.038) 6 (0.041) 0.926 0.860
mir-204 8 (0.009) 3 (0.021) 0.436 0.205
(3) mir-15a 2 (0.002) 4 (0.028) 0.082 0.000
mir-193a 0 (0.000) 1 (0.007) 0 0.013
mir-302b 0 (0.000) 1 (0.007) 0 0.013
mir-184 0 (0.000) 2 (0.014) 0 0.000
(4) mir-183 7 (0.008) 0 (0.000) 0.283
mir-182 6 (0.007) 0 (0.000) 0.321
mir-96 4 (0.005) 0 (0.000) 0.418
mir-183-96-182 15 (0.017) 0 (0.000) 0.115
total 887 145
Notes: the numbers in parentheses indicate their proportion to all papers describing cancer emt (second column) or noncancer emt (third column). ratio: ratio 
between the proportions (the numbers in the parentheses). P-value: probability calculated using two-tailed prop.test for null hypothesis that [proportion in cancer 
emt] = [proportion in noncancer emt]. the top mirs in each of the following four categories are listed: (1) enriched in cancer emt, (2) enriched in both cancer 
and noncancer emt, (3) enriched in noncancer emt, and (4) members of the mir-183-96-182 cluster (individually and in total). for full results, see supplementary 
table 1.
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Inverse correlation between the levels of mir-182 and 
RECK mrNA in breast cancer tissues. Third, we looked 
for miRs that show differential expression between can-
cer and normal tissues with correlation to RECK mRNA 
expression levels. For this purpose, we chose to use TCGA 
breast cancer data in which both mRNA and miR data in 
cancer tissues as well as matched normal tissues were avail-
able (n = 53). As expected, highly significant downregulation 
of RECK mRNA in cancer tissues was observed (P = 0.000; 
Fig. 2A). When we chose the cutoff values of 0.8 and 1.25 
for downregulation and upregulation, respectively, we found 
that RECK mRNA was downregulated in cancer tissue in 47 
patients, upregulated in two patients, and unchanged in four 
patients (Fig. 2B).
In the case of miRs, distribution of the median of the ratio 
(cancer/normal) was roughly symmetrical around zero (in log-
arithmic scale). When cutoff values of 0.5 and 2 were chosen, 
71 miRs were downregulated and 77 miRs were upregulated in 
cancer tissues (Fig. 2C). For a technical reason (to avoid divi-
sion by zero), we assigned the expression value of 0.1 to all 
undetectable miRs. Therefore, the miRs undetectable in both 
cancer and normal tissues would give the ratio of 1. Among the 
638 miRs that gave the ratio of 1 (0 in the log2 scale as shown 
in Fig. 2C), 279 miRs were undetectable in all samples.
Based on these classifications, we compared the changes 
in the expression of RECK mRNA and miRs between can-
cer tissues and matched normal tissues using a newly devel-
oped nonparametric correlation test, named the PDC test (see 
“Methods” section for detail; the distribution of diff.sum based 
on simulation is illustrated in Fig. 2D). Through this method, 
we obtained a list of 1046 miRs, whose expression is similarly 
or inversely correlated with that of RECK mRNA (Table 3; for 
full list, see Supplementary Table 6). In these tables, “diff.sum” 
score represents the extent of inverse correlation between the 
levels of the miR and RECK mRNA. In the present comparison 
of 53 pairs of data, diff.sum scores, by definition, range between 
0 (perfect positive correlation) and 106 (perfect inverse correla-
tion). The diff.sum scores for miR-139 (9) and miR-486-1 (13) 
are among the lowest in the list (Table 3, see also Fig. 2E), indi-
cating that the changes in their expression are concordant to 
that of RECK mRNA in most cases. Interestingly, both miRs 
have been reported as tumor suppressors, and their expression 
has been shown to be inversely correlated with tumor prolifera-
tion or progression.25,26 On the other hand, the diff.sum scores 
for miR-96 (91) and miR-183 (95) are among the highest in the 
list, indicating their inverse correlation with RECK mRNA. 
miR-183, miR-96, and miR-182 are located in close proximity 
on human chromosome 7 and are expressed in a single primary 
transcript.27 Indeed, miR-182 also shows a high diff.sum score 
(90). Of note, several well-studied miRs reported to exhibit 
oncogenic activities, such as miR-21, or those of bidirectional 
activities, such as the miR-200 family (miR- 200a, miR-200b, 
and miR-200c), are also among the high diff.sum score group 
(ie, inversely correlated with RECK mRNA).
teAd4 and soX2 as possible mir-183-96-182 regu-
lators. The above findings prompted us to focus on the miR-
183-96-182 cluster. Besides its inverse correlation in expression 
with RECK (Table 3), two of its members (miR-182 and miR-
96) have the potential to target RECK (Table 2) and at least 
four studies have been published for each member (15 papers 
in total) in the context of cancer EMT, but never in the con-
text of noncancer EMT (Table 1).
The TSS of the miR-183-96-182 primary transcript has 
been predicted to be at 5207 bp upstream of the miR-183 
precursor on human chromosome 7.28 A region of 4 kb sur-
rounding this TSS is rich in nucleosomes with H3K4Me3 
and H3K27Ac modifications, both known to mark active 
transcription. ENCODE ChIP-seq data also indicate bind-
ing of many (∼70) transcription factors within the region of 
about 16 kb surrounding the TSS (Fig. 3A). A survey of gene 
expression databases indicated that several of these factors 
may affect the expression of RECK in various experimental 
settings. For instance, knockdown of TEAD4 resulted in ele-
vated Reck expression in the mouse myogenic cell line C2C12 
(GSE27845, Fig. 3B). Likewise, suppression of Ezh2 resulted 
in elevated Reck expression in high-grade glioma and preadi-
pocytes (GSE63853 and GSE20054, respectively, Supple-
mentary Fig. 5A and B). No miR-183-96-182 expression data 










mir-182 2.46 0.987 0.72 −0.29 −1.3325
mir-429 1 0.9 −0.28 −1.323
mir-200b 0.999 0.9 −0.29 −1.3226
mir-200c 1.66 0.999 0.9 −0.29 −1.3187
mir-195 2.84 0.995 0.89 −0.34 −1.3113
mir-424 0.97 0.89 −0.36 −1.3107
mir-15b 2.84 0.997 0.89 −0.39 −1.3072
mir-15a 2.84 0.997 0.89 −0.38 −1.3072
mir-497 0.972 0.89 −0.38 −1.3065
mir-590 0.961 0.63 −0.34 −1.2763
mir-21 1.79 1 0.63 −0.35 −1.2763
mir-221 0.741 0.31 −0.33 −1.2621




mir-96 2.46 0.73 −0.13 −0.5472
mir-183
Notes: mirs with a mirsVr score smaller than −1.2 and members of mir-
183-96-182 are shown. for full lists, see supplementary tables 2–5. Lower 
values predict higher probabilities of RECK-targeting in the case of mirsVr 
(miranda) and Context score (targetscan), while higher scores predict higher 
probabilities in the case of Picrar score, mitG score (microt-CDs), and PCt 
(targetscan).
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A
25 P = 0.000
P = 0.000




diff.sum = 9 P = 0.004 P = 0.005diff.sum = 13 diff.sum = 14
P = 0.797diff.sum = 56P = 0.749diff.sum = 53P = 0.652diff.sum = 50
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figure 2. PDC test for RECK mrna and various mirs in paired tCGa breast cancer samples. (A) expression of RECK mrna in 53 pairs of cancer and 
matched normal tissues in tCGa breast cancer dataset. the boxes indicate the interquartile range (IQr) of data between 75% (Q3) and 25% (Q1). the bars 
below and above each box indicate the data in Q1 − 1.5 × IQr and Q3 + 1.5 × IQr, respectively. P-value was calculated by paired t-test. (B) ratio (in log2) of 
the RECK mrna levels between cancer and normal tissues from 53 breast cancer patients. Blue and red broken lines indicate the cutoff values for “Down” 
(0.8) and “Up” (1.25) groups, respectively. (C) median of ratios (in log2) of the levels of mirs (1046 species) among 53 pairs of cancer and normal tissues. 
Blue and red broken lines indicate the cutoff values for “Down” (0.5) and “Up” (2.0) groups, respectively. (d) Distribution of diff.sum based on random shuffling 
of original mirs diff matrix and then generating a 1000 times larger simulated dataset (see “methods” section for details). (E) relationship between the levels 
(in log2) of RECK mrna and various mirs. top row: mirs with low diff.sum scores (positive correlation). middle row: mirs with intermediate diff.sum scores. 
Bottom row: mirs with high diff.sum scores (inverse correlation). red spots represent cancer samples and blue spots represent normal tissue samples. Gray 
line represents regression curve. P represents the cumulative probability obtained from the distribution showed in (d), and values sufficiently close to 0 or 1 
both indicate a rare event. for more completed scatter between top mirs with low/high diff.sum scores and RECK mrna, see supplementary figures 2 and 3.
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Table 3. mirs exhibiting positive or inverse correlation in expression with RECK mrna among the matched breast cancer and normal breast 
tissues from 53 patients (tCGa data).
RANKiNg miR diff.sum P REfERENCES SUMMARY
t1 mir-139 9 0.000 24204738, 24942287 tumor suppressor
t2 mir-486-1 13 0.004 25104088, 21415212 tumor suppressor
t3 mir-10b 14 0.005 21067538, 18948893 Context-dependent oncomir or bidirectional?
t3 mir-195 14 0.005 24402230, 24787958 tumor suppressor 
t3 mir-204 14 0.005 25157435, 23204229 tumor suppressor 
t6 mir-451a 15 0.008 24918822, 24841638 tumor suppressor 
t6 mir-99a 15 0.008 24957100, 21878637 tumor suppressor 
t8 mir-140 16 0.009 23401231, 24971538 tumor suppressor 
t8 mir-584 16 0.009 21119662 tumor suppressor 
t10 mir-100 17 0.013 24586203 Bidirectional
t10 mir-1247 17 0.013 24785261 tumor suppressor 
t10 mir-125b-2 17 0.013 22711523 tumor suppressor
t10 mir-133a1 17 0.013 23723074, 25198665 tumor suppressor
t10 mir-144 17 0.013 25073510, 25961751 tumor suppressor
… … … … …
B41 mir-200c 76 0.963 25826661, 18376396 Bidirectional, targets RECK
B33 mir-200b 77 0.968 25826661, 18376396 Bidirectional, targets RECK
B33 mir-7-1 77 0.968 22761427, 25027403 Bidirectional, targets RECK
B8 mir-141 85 0.991 25003366, 25008569 Bidirectional
B8 mir-200a 85 0.991 23679328, 25239643 Bidirectional
B8 mir-301b 85 0.991 24398967 oncomir
B8 mir-92b 85 0.991 24162673, 23416699 oncomir, targets RECK
B7 mir-429 87 0.995 24866238, 24572141 oncomir
B6 mir-1301 88 0.995 22159405 Possible tumor suppressor
B5 mir-182 90 0.997 23383207, 23333633 oncomir, targets RECK
B3 mir-21 91 0.998 20447717, 25084400 oncomir, targets RECK
B3 mir-96 91 0.998 24366472, 24469470 oncomir, targets RECK
B2 mir-592 92 0.999 Unknown
B1 mir-183 95 1.000 23538390, 25337200 Bidirectional
Notes: representative references are cited (PmID). ranking: t, from top; B, from bottom. P represents the cumulative probability. for full list, see supplementary 
table 6.
are available from these experiments. Paradoxically, however, 
knockdown of EZH2 resulted in elevated expression of miR-
183, miR-182, and miR-182* in the prostate cancer cell line 
DU145 (GSE26996, Supplementary Fig. 5C). No RECK 
expression data are available from this experiment.
We also surveyed the effects of additional 30 fac-
tors, mainly oncogenes and EMT regulators, on RECK 
and miR-183-96-182 expression. This survey detected 
SOX2, whose knockdown influenced the expression of the 
miR-183-96-182 cluster and RECK. In one dataset (GSE67993), 
SOX2 knockdown in human embryonic stem cells resulted 
in downregulation of miR-182/miR-96 and upregulation of 
RECK mRNA (Fig. 3C). In another dataset (GSE49403), 
knockdown of SOX2 or its coregulator RMST in neural stem 
cells resulted in upregulation of RECK mRNA (Fig. 3D), 
although this dataset did not provide information on miR-183-
96-182 expression. In addition, another dataset (GSE59380) 
indicated that knockdown of SOX2 in the embryonal 
carcinoma cell line 2102Ep resulted in downregulation 
of miR-183/miR-182.29
discussion
Utility of the Pdc test developed in this study. One 
of the questions we attempted to address in this study was 
when the level of RECK mRNA changes (between cancer 
and normal tissues), how the levels of various miRs change in 
the same patient. The change in this case can be qualitative, 
since it involves intrinsic differences between cancer tissue and 
the corresponding normal tissue. Our PDC test is a simple 
approach to make such comparisons possible. In this test, we 
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cause unnecessary loss of information. In the case of miRs, 
however, more robust cutoff values of 0.5 should be more 
appropriate in light of their mechanism of action. However, 
even when we chose more stringent conditions (cutoff values 
figure 3. Candidates for the transcription factors regulating the mir-183-96-182 cluster. (A) the 23-kb human genomic region containing the mir-183-
96-182 cluster as shown in the UCsC genome browser. three mirs, soX2, and teaD4 are highlighted by red boxes. mYC and eZH2 are underlined. 
the binding site for soX2 is based on Vencken’s meta-analysis (PmID: 25156079). tss of pri-mir-183-96-182 is based on Chien et al (PmID: 21821656). 
(B) effects of teaD4 knockdown (KD) on the level of Reck mrna in differentiated C2C12 cells. shsC, control shrna; sha and shB, two independent 
shrnas targeting teaD4; n = 1. (C) effects of soX2 KD on the levels of mir-182, mir-96, and RECK mrna in undifferentiated human embryonic stem 
cells. Wt, treated with scrambled sirna; soX2 KD, treated with soX2 sirna; n = 1. (d) effects of knocking down soX2 or RMST on the level of RECK 
mrna in neural stem cells. si-nt, control sirna; si-rmst and si-soX2, sirna targeting RMST and soX2, respectively; n = 1. (B), (C), and (d) are 
based on the following nCBI Geo datasets, respectively, Gse27845, Gse67993, and Gse49403.
can choose cutoff values depending on the nature of the data 
being compared. For example, the levels of RECK mRNA are 
known to be generally low among cancer samples, and there-
fore, a too strict cutoff value (eg, 0.5) for downregulation may 


















figure 4. Model consistent with our findings. In cancer cells, transcription factors such as SOX2 and TEAD4 are upregulated and induce miR-182-96-183 
expression. three mirs in turn promote emt, while two of them (mir-182 and mir-96) target RECK mrna. the positive feedback loop between emt 
and mir-182-96-183 works to stably downregulate reCK after emt.
of 0.5 and 2 for both RECK mRNA and miRs), the top five 
miRs detected in this study were the same, albeit in differ-
ent order, demonstrating the robustness of this method. Nev-
ertheless, the adjustability of cutoff values should make this 
method useful in wider applications.
In this study, the PDC test was successfully used for enrich-
ing miRs, whose expression are positively or inversely corre-
lated with RECK expression. Of note, among the top 14 miRs 
with positive correlation with RECK mRNA (diff.sum #17, 
P # 0.013; Table 3, Ranking T1–T10), 12 miRs have previously 
been reported to have tumor suppressor function (Table 3). 
Among the top 11 miRs with inverse correlation with RECK 
mRNA (diff.sum $85, P $ 0.991; Table 3, Ranking B1–B8), 
6 miRs have previously been reported as oncomiRs, and impor-
tantly, 4 of them (miR-96,30–32 miR-21,33–36 miR-182,37–39 and 
miR-92b40) target RECK directly. Furthermore, additional 
three miRs reported to target RECK mRNA (miR-7-1,36 miR-
200b,41 and miR-200c41) are also found within the top 41 in 
this category. Hence, this approach seems to be useful for pre-
dicting potential oncomiRs and tumor suppressor miRs and, in 
more general, for predicting potential miR-target relationship.
Classical theory holds that miRs repress target gene 
expression through two mechanisms as follows: (1) perfect or 
nearly perfect base pairing with the target mRNA promotes 
cleavage of the mRNA and (2) partially complementary miRs 
inhibit translation of target mRNAs. However, more recent 
findings indicate that translational inhibition by partially 
complementary miRs is also accompanied by accelerated deg-
radation of target mRNA.42 Our approach (to find miRs that 
target RECK and show inverse correlation in expression with 
RECK) is based on this new understanding.
mir-183-96-182 may uncouple recK expression from 
eMt in cancer. We used three approaches to find candidate 
miRs that play roles in RECK suppression after EMT in 
cancer cells. The first approach of surveying published reports 
in PubMed has an advantage that these findings have been 
experimentally validated, but it also has disadvantages such as 
the large influence of key word choice and the arbitrary nature 
of the areas covered by current literature. The second approach 
of finding miR targets using multiple algorithms is more 
objective and genome wide (advantage), but the results are not 
always accompanied by experimental validation (disadvantage). 
The third approach of finding miRs with correlated changes in 
expression with a target gene is also objective and genome wide 
(advantage), but the results largely depend on the datasets used 
and do not usually provide any information on the mechanism 
of correlated changes (disadvantage). Although the results 
obtained through each approach may have limited value for 
identifying feasible candidates, the miRs detected by multiple 
approaches should be of particular interest.
The members of the miR-183-96-182 cluster were detected 
by all three approaches. First, these miRs are enriched in the 
abstracts related to cancer EMT studies (Table 1). Second, 
miR-182 was among the top-ranking miRs predicted to target 
RECK by all the algorithms used. miR-96 was also predicted 
to target RECK, albeit at lower ranking (Table 2). Third, 
miR-183, miR-96, and miR-182 were among the top-ranking 
miRs with inverse correlation with RECK in our PDC test 
(Table 3). Indeed, Hirata et al already showed that miR-182 
could suppress RECK expression in cell lines derived from 
bladder cancer38 and prostate cancer.39 Multiple studies also 
indicate that miR-96 targets RECK.30–32
Several findings suggest the causative role of miR-183-
96-182 in cancer EMT. Yang et al found that overexpres-
sion of miR-182 enhanced cell proliferation, invasion, and 
migration and induced molecular features of EMT, including 
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upregulation of Snail and Vimentin with concomitant down-
regulation of E-cadherin.43 In a recent study, the three members 
of miR-183-96-182 cluster were found to promote EMT in 
breast cancer cells.44 However, multiple lines of evidence place 
miR-183-96-182 downstream of EMT as well. In gallblad-
der cancer cells, TGFβ was found to induce miR-182 expres-
sion, and inhibition of miR-182 resulted in suppression of 
TGFβ-induced cancer cell migration and invasion.45 Although 
TGFβ is not equivalent to EMT, it is commonly used to induce 
EMT in cultured cells. Likewise, glioma cells treated with 
TGFβ showed remarkable increase in the expression of miR-
182, miR-183, and miR-96.46 Taken together, these reports 
suggest a positive feedback loop between EMT and miR-183-
96-182 in cancer cells. Interestingly, TGFβ showed no effect on 
miR-182 expression in normal human astrocytes,46 supporting 
the idea that miR-182 may be involved in cancer-specific inhi-
bition of RECK induction after EMT. Further strengthening 
this idea, miR-182 was downregulated after EMT in a prostate 
epithelial cell line (noncancerous).47 However, this study was 
categorized into “cancer EMT” (Table 1) because the abstract 
contains the terms “cancer” and “metastasis”, exemplifying 
a potential pitfall in such text-mining approaches.
miR-183-96-182 or its components are overexpressed 
in various cancers and may play positive roles in carcino-
genesis.43,44,48–51 Higher expression of the miR-183-96-182 
cluster (as a whole or in part) in breast cancer cell lines com-
pared with the MCF10A human breast epithelial cell line has 
also been reported in multiple studies.27,32 However, there are 
several studies reporting a inverse correlation between miR-
183-96-182 or its components and malignancy,52,53 suggesting 
context-dependency of their actions.
Possible regulators of mir-183-96-182 expression. 
Several molecules such as β-catenin/TCF/LEF,54 p53,55 and 
TGFβ46 have been implicated in the regulation of miR-183-
96-182 expression.48 In this study, however, we found some 
evidence suggesting SOX2 and TEAD4 as potential regula-
tors of miR-183-96-182 expression.
SOX2 seems to have multiple effects on carcinogenesis: 
in lung cancer, SOX2 expression has been correlated with bet-
ter prognosis,56,57 while in esophageal cancer, SOX2 amplifi-
cation and/or overexpression has been associated with poorer 
prognosis.58 In breast cancer, high SOX2 expression has been 
associated with cancer formation and malignancy.59–61 From 
three datasets on SOX2 knockdown experiments, we found 
evidence supporting the model that SOX2 suppresses RECK 
expression via upregulation of miR-183-96-182 in cancer 
cells (Fig. 4). Through a meta-analysis of two sets of SOX2 
chromatin immunoprecipitation data using human embryonic 
stem cells, Vencken et al.29 suggested a SOX2-binding site at 
∼4 kb upstream of the predicted miR-183 TSS (Fig. 3A); in 
that study, however, SOX2 was considered to be an inhibitor of 
EMT during embryonic development. In the context of cancer, 
however, SOX2 has been reported to bind to the promoters of 
SNAIL, SLUG, and TWIST and to promote EMT,62 which fits 
with our model. Induction of Sox2 by TGF-β has also been 
reported.63 Thus, although multiple lines of evidence in the 
databases support the involvement of SOX2 in the pathway 
proposed here (Fig. 4), the evidence is fragmentary and not 
always in comparable contexts.
TEAD4, a member of the TEAD family, plays crucial 
roles in mammalian development and carcinogenesis and is 
overexpressed in various types of cancer (Supplementary 
Fig. 4). Knockdown of TEAD4 in C2C12 cells resulted in 
marked upregulation of Reck expression (Fig. 3D). Based on 
ENCODE ChIP-seq data, the nearest TEAD4-binding site 
is quite distant in the case of RECK (27.8 kb upstream of 
TSS) but very close in the case of miR-183-96-182 (0.2 kb 
upstream of TSS) (Fig. 3A). In ovarian cancer, increased 
TEAD4 expression predicts poorer prognosis, and increased 
expression of both YAP and TEAD4 shows even more dra-
matic association with poor prognosis.64 While this article was 
under revision, Liu et al published a study reporting TEAD4 
overexpression in colorectal cancer and its activity to promote 
EMT by activating Vimentin expression.65 Herein, we sug-
gest that RECK inhibition via miR-183-96-182 activation 
may also be involved in TEAD4-induced malignant behav-
iors of cancer cells after EMT (Fig. 4).
conclusions
Through multiple in silico approaches, we aimed to narrow down 
the candidate miRs possibly involved in cancer-specific sup-
pression of EMT-induced RECK upregulation. Two oncomiRs 
(miR-182 and miR-96) closely clustered on human chromo-
some 7 show inverse correlation in expression with RECK, 
are capable of directly targeting RECK, and have previously 
been implicated both upstream and downstream of EMT in 
cancer cells. We also predict that transcription factors such as 
SOX2 and TEAD4 may enhance the expression of the miR-
183-96-182 cluster from which miR-182 and miR-96 are 
produced (Fig. 4).
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